- Heart transplant rejection prophylaxis:
- Adults: PO 0.075mg/kg/day divided BD
- Children: PO 0.3mg/kg/day divided BD OR PO 0.1mg/kg/day divided BD if cell depleting induction treatment given
- Use 6 hours post-transplant
- Can be used with azathioprine or mycophenolate mofetil
- Liver transplant rejection prophylaxis:
- Adults: PO 0.1-0.15 mg/kg/day divided BD
- Children: PO 0.15-0.2mg/kg/day divided BD
- Use with corticosteroids
- Use 6 hours post-transplant
- Kidney transplant rejection prophylaxis:
- Adults: PO 0.1-0.2mg/kg/day divided BD
- Children: PO 0.3mg/kg/day divided BD
- Used within 24 hours post-transplant
- Lung transplant rejection prophylaxis:
- Adults: PO 0.075mg/kg/day divided BD
- Children: PO 0.3mg/kg/day divided BD OR PO 0.1mg/kg/day divided BD if cell depleting induction treatment given
- Use 6 hours post-transplant
- Can be used with azathioprine or mycophenolate mofetil
Tablet/capsule: 0.5mg; 1mg; 5mg
- Capsule: administered consistently with or without food
- Tablet: taken preferably on an empty stomach
Calcineurin inhibitor; Immunosuppressant
It is thought to inhibit T-cell activation and proliferation, humoral immunity
- Tremor
- Diarrhea
- Headache
- Hypertension
- Increased Cr
- Infection
- Nausea
- Vomiting
- Insomnia
- Pain
- Hypophosphatemia
- Constipation
- Asthenia
- Peripheral edema
- Hypomagnesemia
- Fever
- Anemia
- Diabetes mellitus
- Paresthesia
- Elevated LFTs
- Hyperlipidemia
- Hyperkalemia
- Anorexia
- Dyspepsia
- Arthralgia
- Dyspnea
- Pruritus
- Rash
- Hypokalemia
- Dizziness
- Cough
- Leukopenia
- Photosensitivity
- Bronchitis
- Hypersensitivity to class/components
- Uncorrected electrolyte abnormalities
- Congenital long QT syndrome
WARNING
- Increased risk of infections, lymphomas and other malignancies in patients receiving immunosuppressants
- Amphotericin B deoxycholate
- Cidofovir
- Dronedarone
- Elagolix
- Fluconazole
- Lefamulin
- Mifepristone
- Oral neomycin
- Saquinavir
- Thioridazine
- Ziprasidone
- Live vaccines
- Ritonavir
- Talimogene
Drug Status
| Availability | Prescription only |
| Pregnancy | Category C; Weigh risk vs benefit |
| Breastfeeding | Benefit outweighs risk |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Adoport | 500mcg | Capsule | 60’s | Sandoz GMBH | Novartis Kenya |
| Adoport | 1mg | Capsule | 60’s | Sandoz GMBH | Novartis Kenya |
| Adoport | 5mg | Capsule | 60’s | Sandoz GMBH | Novartis Kenya |
| Advagraf | 0.5mg | Tablet | 30’s | Astellas Pharma | Harley’s Ltd |
| Advagraf | 1mg | Tablet | 30’s | Astellas Pharma | Harley’s Ltd |
| Advagraf | 5mg | Capsule | 30’s | Astellas Pharma | Harley’s Ltd |
| Imugraft | 0.03% w/w | Ointment | 10g | Rainbow Life Sciences | Europa Healthcare |
| Pangraf | 0.5mg | Capsule | 60’s | Panacea Biotec | Europa Healthcare |
| Pangraf | 1mg | Capsule | 60’s | Panacea Biotec | Europa Healthcare |
| Pangraf | 5mg | Capsule | 10’s | Panacea Biotec | Europa Healthcare |
| Tacrocord | 1mg | Capsule | 60’s | Concord Biotech | Wessex Pharma |
| Tacrocord | 5mg | Capsule | 60’s | Concord Biotech | Wessex Pharma |
| Tacrocord | 0.5mg | Capsule | 60’s | Concord Biotech | Wessex Pharma |
| Tacrotas | 1mg | Capsule | 100’s | Intas Pharma | Accord Healthcare |
| Tacrotas | 0.5mg | Capsule | 100’s | Intas Pharma | Accord Healthcare |
| Tacrovate | 0.03% w/w | Ointment | 10g | Ochoa Labs | Medisel Kenya |
| Vingraf | 1mg | Capsule | 60’s | Emcure Pharma | Lazor Pharma |
| Vingraf | 5mg | Capsule | 60’s | Emcure Pharma | Lazor Pharma |